The Medicines Manufacturing Innovation Centre (MMIC)

  • Innovative research and development facility supporting the UK’s pharmaceutical and fine chemicals industry in accelerating manufacturing processes
  • Fluid and dynamic design allowing for reconfiguration and expansion
  • A catalyst project, paving the way for future development on the wider campus
Client: CPI

An innovative research, development and manufacturing facility, the new Medicines Manufacturing Innovation Centre (MMIC) in Renfrewshire will support the UK’s pharmaceutical and fine chemicals industries in accelerating a new generation of manufacturing processes.

A joint project between CPI, the University of Strathclyde, UK Research and Innovation, Scottish Enterprise, GSK and AstraZeneca, the Centre will provide academics, research scientists and manufacturing partners with access to cutting-edge technical equipment and knowledge. It aims to encourage collaboration to develop new technologies and processes that will increase productivity in medicines manufacturing.

BakerHicks have been supporting CPI and their partners in the project since 2015, facilitating industry-wide stakeholder workshops and evaluated design options to develop the project brief.

In 2019, they were appointed to deliver multidisciplinary design services, including architecture, civil and structural, mechanical and electrical, pharmaceutical consultancy, and process engineering, to RIBA Stage 3. The team are now working closely with the main contractor to provide a principal designer advisory role as the project progresses towards construction.

Reacting to industry needs

The Covid-19 outbreak led to the building being given ‘essential’ status, supporting the programme to allow for the completion of RIBA Stage 4 (Technical Design) and the appointment of specialist sub-contractors via the main contractor. Ground was broken on the project in October 2020.

With a number of different processes needing to be accommodated, and the specifics of these not necessarily known, the facility is designed to be as fluid and dynamic as possible. The space can be reconfigured easily, and a column-free design allows for further expansion, including clean rooms and warehousing, ensuring the Centre can react to the needs of the industry.

Full stakeholder collaboration and cooperation have been key throughout, with a coordinated approach supported by working to BIM Level 2.

A stepping stone

Part of the Advanced Manufacturing Innovation District Scotland (AMIDS), whose vision is to bring together similar companies to better harness new technologies, the MMIC is intended as a catalyst for future development.

Our teams worked closely with all stakeholders to develop a solution that met the needs of both the MMIC and the wider campus’ vision, including looking at campus infrastructure and utilities, circulation patterns around future development, maintenance of views in and out of the site, and designing a building that achieved the aim of being a stepping stone for future projects.

The Centre is supported by a £13 million investment from UK Research and Innovation through the Industrial Strategy Challenge Fund (ISCF), along with £15 million from Scottish Enterprise and £7 million from both GSK and AstraZeneca.